The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Mobiflex     (4E)-4-[hydroxy-(pyridin-2...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Tilcotil


Psychiatry related information on Tilcotil


High impact information on Tilcotil

  • The patients were randomized in two groups, as follows: G1 (n = 76): IFNalpha2a 3 million units times per week during 6 months + placebo; and G2 (n = 73): IFNalpha2a 3 million units three times per week + Tenoxicam (20 mg/day) during 6 months [1].
  • The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma [2].
  • Thirteen patients with rheumatoid arthritis (mean +/- SD age 55.8 +/- 10.5 years) received 20 mg of tenoxicam daily for 90 days following a 3-7 day "washout" period and 4 days of placebo treatment [8].
  • CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians [9].
  • OBJECTIVE: Cytochrome P450 (CYP) 2C9, the product of the polymorphic gene CYP2C9, provides the major catabolic pathway for several anti-inflammatory drugs, including tenoxicam [9].

Chemical compound and disease context of Tilcotil


Biological context of Tilcotil


Anatomical context of Tilcotil

  • Total tenoxicam concentrations in synovial fluid were always less than those in plasma, and there was little fluctuation in plasma or synovial concentrations over the dosage interval, although there was substantial inter-subject variation in both concentrations [2].
  • Involvement of leukocyte peroxidases in the metabolism of tenoxicam [17].
  • Effects of tenoxicam and aspirin on the metabolism of proteoglycans and hyaluronan in normal and osteoarthritic human articular cartilage [18].
  • We studied 32 patients undergoing bilateral symmetrical lower third molar surgery under general anaesthesia to determine if the combined effects of pre-emptive local anaesthetic block using 0.5% bupivacaine, together with i.v. tenoxicam and alfentanil had any benefits over postoperative administration [19].
  • To investigate the transfer of different NSAIDs via the lymphatic system, pharmacokinetics in plasma and lymph after peroral administration of three model compounds (namely, racemic ibuprofen, tenoxicam, and nabumetone) were investigated in rats [20].

Associations of Tilcotil with other chemical compounds


Gene context of Tilcotil


Analytical, diagnostic and therapeutic context of Tilcotil

  • All-night polysomnography was performed in a sleep laboratory during the last 2 days of placebo treatment and on days 13, 14, 89, and 90 of tenoxicam treatment [8].
  • Tenoxicam is presently undergoing clinical trials [31].
  • RESULTS: The incidence of postepidural backache in patients in the control group for the 3 days were 22.8%, 17.4%, and 9.2%, all of which were significantly more frequent than observed in the patients in the tenoxicam group (6.8%, 4.0%, and 1.2%, P < 0.01) [32].
  • METHODS: We performed a prospective, randomized, double-blind study to compare the effect of local addition of tenoxicam on the incidence of postepidural backache after nonobstetric surgery [32].
  • The local addition of tenoxicam reduces the incidence of low back pain after lumbar epidural anesthesia [32].


  1. Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon. Zarski, J.P., Maynard-Muet, M., Chousterman, S., Baud, M., Barnoud, R., Abergel, A., Bacq, Y., Combis, J.M., Causse, X., Tran, A., Oberti, F., Minello, A., Bresson-Hadni, S., Bailly, F., Raabe, J.J., Leroy, V., Hamici, L., Hicham, T., Girardin, M.F. Hepatology (1998) [Pubmed]
  2. The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. Day, R.O., Williams, K.M., Graham, S., Handel, M. Arthritis Rheum. (1991) [Pubmed]
  3. Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Gonzalez, J.P., Todd, P.A. Drugs (1987) [Pubmed]
  4. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Quijada-Carrera, J., Valenzuela-Castaño, A., Povedano-Gómez, J., Fernández-Rodriguez, A., Hernánz-Mediano, W., Gutierrez-Rubio, A., de la Iglesia-Salgado, J.L., García-López, A. Pain (1996) [Pubmed]
  5. Prolonged cholestasis and ductopenia associated with tenoxicam. Trak-Smayra, V., Cazals-Hatem, D., Asselah, T., Duchatelle, V., Degott, C. J. Hepatol. (2003) [Pubmed]
  6. Patient compliance with tenoxicam in family practice. Kraag, G.R., Gordon, D.A., Ménard, H.A., Russell, A.S., Kalish, G.H. Clinical therapeutics. (1994) [Pubmed]
  7. The evaluation of a nonsteroidal anti-inflammatory drug (tenoxicam) in the treatment of sleep disturbance in osteoarthritic patients. Leigh, T.J., Bird, H.A., Hindmarch, I., Wright, V. Clin. Rheumatol. (1989) [Pubmed]
  8. Nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis patients. Lack of association between clinical improvement and effects on sleep. Lavie, P., Nahir, M., Lorber, M., Scharf, Y. Arthritis Rheum. (1991) [Pubmed]
  9. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Vianna-Jorge, R., Perini, J.A., Rondinelli, E., Suarez-Kurtz, G. Clin. Pharmacol. Ther. (2004) [Pubmed]
  10. Enhanced sonodynamic antitumor effect of ultrasound in the presence of nonsteroidal anti-inflammatory drugs. Sakusabe, N., Okada, K., Sato, K., Kamada, S., Yoshida, Y., Suzuki, T. Jpn. J. Cancer Res. (1999) [Pubmed]
  11. A multicenter study of tenoxicam and diclofenac in patients with osteoarthritis of the knee. Bellamy, N., Buchanan, W.W., Chalmers, A., Ford, P.M., Kean, W.F., Kraag, G.R., Gerecz-Simon, E., Campbell, J. J. Rheumatol. (1993) [Pubmed]
  12. The effect of intravenous tenoxicam on pruritus in patients receiving epidural fentanyl. Colbert, S., O'Hanlon, D.M., Chambers, F., Moriarty, D.C. Anaesthesia. (1999) [Pubmed]
  13. Comparison of efficacy of intraarticular application of tenoxicam, bupivacaine and tenoxicam: bupivacaine combination in arthroscopic knee surgery. Talu, G.K., Ozyalçin, S., Koltka, K., Ertürk, E., Akinci, O., Aşik, M., Pembeci, K. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA. (2002) [Pubmed]
  14. Clinical pharmacokinetics of tenoxicam. Nilsen, O.G. Clinical pharmacokinetics. (1994) [Pubmed]
  15. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Olkkola, K.T., Brunetto, A.V., Mattila, M.J. Clinical pharmacokinetics. (1994) [Pubmed]
  16. Clinical tolerability of perioperative tenoxicam in 1001 patients--a prospective, controlled, double-blind, multi-centre study. Merry, A.F., Webster, C.S., Holland, R.L., Middleton, N.G., Schug, S.A., James, M., McGrath, K.A. Pain (2004) [Pubmed]
  17. Involvement of leukocyte peroxidases in the metabolism of tenoxicam. Ichihara, S., Tomisawa, H., Fukazawa, H., Tateishi, M. Biochem. Pharmacol. (1985) [Pubmed]
  18. Effects of tenoxicam and aspirin on the metabolism of proteoglycans and hyaluronan in normal and osteoarthritic human articular cartilage. Manicourt, D.H., Druetz-Van Egeren, A., Haazen, L., Nagant de Deuxchaisnes, C. Br. J. Pharmacol. (1994) [Pubmed]
  19. Balanced pre-emptive analgesia: does it work? A double-blind, controlled study in bilaterally symmetrical oral surgery. Campbell, W.I., Kendrick, R.W., Fee, J.P. British journal of anaesthesia. (1998) [Pubmed]
  20. Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. Oelkers, R., Ionac, M., Erb, K., Brune, K., Geisslinger, G. Drug Metab. Dispos. (1996) [Pubmed]
  21. Effect of anti-inflammatory drugs on splenocyte membrane fluidity. Ferreira, H., Lúcio, M., Lima, J.L., Cordeiro-da-Silva, A., Tavares, J., Reis, S. Anal. Biochem. (2005) [Pubmed]
  22. The analgesic efficacy of intravenous tenoxicam as an adjunct to patient-controlled analgesia in total abdominal hysterectomy. Danou, F., Paraskeva, A., Vassilakopoulos, T., Fassoulaki, A. Anesth. Analg. (2000) [Pubmed]
  23. Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on Aceclofenac in Ankylosing Spondylitis. Villa Alcázar, L.F., de Buergo, M., Rico Lenza, H., Montull Fruitós, E. J. Rheumatol. (1996) [Pubmed]
  24. Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers. Day, R.O., Geisslinger, G., Paull, P., Williams, K.M. British journal of clinical pharmacology. (1994) [Pubmed]
  25. Pain after primary inguinal herniorrhaphy: influence of surgical technique. Callesen, T., Bech, K., Andersen, J., Nielsen, R., Roikjaer, O., Kehlet, H. J. Am. Coll. Surg. (1999) [Pubmed]
  26. Expression of recombinant human cyclooxygenase isoenzymes in transfected COS-7 cells in vitro and inhibition by tenoxicam, indomethacin and aspirin. Lora, M., Morisset, S., Ménard, H.A., Leduc, R., de Brum-Fernandes, A.J. Prostaglandins Leukot. Essent. Fatty Acids (1997) [Pubmed]
  27. In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450. Zhao, J., Leemann, T., Dayer, P. Life Sci. (1992) [Pubmed]
  28. In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis. Ozgocmen, S., Ardicoglu, O., Erdogan, H., Fadillioglu, E., Gudul, H. Ann. Clin. Lab. Sci. (2005) [Pubmed]
  29. Tenoxicam. An update of its pharmacology and therapeutic efficacy in rheumatic diseases. Todd, P.A., Clissold, S.P. Drugs (1991) [Pubmed]
  30. Tenoxicam exerts a neuroprotective action after cerebral ischemia in rats. Galvão, R.I., Diógenes, J.P., Maia, G.C., Filho, E.A., Vasconcelos, S.M., de Menezes, D.B., Cunha, G.M., Viana, G.S. Neurochem. Res. (2005) [Pubmed]
  31. Analogues and derivatives of tenoxicam. 1. Synthesis and antiinflammatory activity of analogues with different residues on the ring nitrogen and the amide nitrogen. Binder, D., Hromatka, O., Geissler, F., Schmied, K., Noe, C.R., Burri, K., Pfister, R., Strub, K., Zeller, P. J. Med. Chem. (1987) [Pubmed]
  32. The local addition of tenoxicam reduces the incidence of low back pain after lumbar epidural anesthesia. Wang, Y.L., Hsieh, J.R., Chung, H.S., Yu, C.L., Ho, A.C., Lu, P.P., Tan, P.P. Anesthesiology (1998) [Pubmed]
WikiGenes - Universities